Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (-6.93%) As of 05/23/2025 10:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. INDP, GNPX, AIM, CHRO, BFRI, ALBT, SNGX, AEZS, LIPO, and MTVAShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Indaptus Therapeutics (INDP), Genprex (GNPX), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), Biofrontera (BFRI), Avalon GloboCare (ALBT), Soligenix (SNGX), Aeterna Zentaris (AEZS), Lipella Pharmaceuticals (LIPO), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Indaptus Therapeutics Genprex AIM ImmunoTech Chromocell Therapeutics Biofrontera Avalon GloboCare Soligenix Aeterna Zentaris Lipella Pharmaceuticals MetaVia Indaptus Therapeutics (NASDAQ:INDP) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking. Which has more volatility and risk, INDP or ADXS? Indaptus Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Do insiders & institutionals have more ownership in INDP or ADXS? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate INDP or ADXS? Indaptus Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 2,203.52%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Indaptus Therapeutics is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is INDP or ADXS more profitable? Ayala Pharmaceuticals' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Ayala Pharmaceuticals N/A N/A N/A Does the MarketBeat Community prefer INDP or ADXS? Indaptus Therapeutics received 13 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%Ayala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes87100.00% Which has stronger earnings and valuation, INDP or ADXS? Indaptus Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.49-0.25Ayala Pharmaceuticals$3.24M0.46-$48.07M-$7.980.00 Does the media favor INDP or ADXS? In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score. Company Overall Sentiment Indaptus Therapeutics Neutral Ayala Pharmaceuticals Neutral SummaryIndaptus Therapeutics beats Ayala Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49M$6.46B$5.33B$8.31BDividend YieldN/A2.63%5.27%4.09%P/E Ratio0.008.3626.7119.58Price / Sales0.46258.94395.60135.07Price / CashN/A65.8538.3234.62Price / Book-0.026.416.764.50Net Income-$48.07M$143.73M$3.23B$248.40M7 Day PerformanceN/A0.31%0.36%-0.85%1 Month PerformanceN/A0.14%7.03%8.09%1 Year PerformanceN/A0.31%18.59%8.75% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-6.9%N/A-83.8%$1.49M$3.24M0.0020News CoverageAnalyst ForecastGap DownINDPIndaptus Therapeutics2.7009 of 5 stars$0.42+3.9%$8.50+1,941.8%-84.4%$6.68MN/A-0.246Gap DownGNPXGenprex0.9101 of 5 stars$0.28-3.3%$10.00+3,523.2%-87.6%$6.67MN/A0.0020AIMAIM ImmunoTech1.5717 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.0%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeCHROChromocell TherapeuticsN/A$1.08-1.9%N/A-31.7%$6.59MN/A-0.734Gap UpBFRIBiofrontera2.6562 of 5 stars$0.68-1.8%$7.00+925.6%-39.6%$6.45M$37.32M-0.3070Analyst RevisionGap DownALBTAvalon GloboCare0.5637 of 5 stars$3.87-0.5%N/A-16.5%$6.39M$1.33M-0.195News CoverageUpcoming EarningsGap DownSNGXSoligenix0.9625 of 5 stars$1.96-1.3%N/A-68.5%$6.38M$840,000.00-0.2620AEZSAeterna ZentarisN/A$3.55+5.0%N/A-57.0%$6.37M$2.37M-0.2420LIPOLipella Pharmaceuticals0.7204 of 5 stars$2.45+1.9%N/A-44.8%$6.23M$536,357.00-0.584Positive NewsMTVAMetaVia1.7082 of 5 stars$0.70-3.9%$12.00+1,612.6%N/A$6.07MN/A0.008 Related Companies and Tools Related Companies Indaptus Therapeutics Alternatives Genprex Alternatives AIM ImmunoTech Alternatives Chromocell Therapeutics Alternatives Biofrontera Alternatives Avalon GloboCare Alternatives Soligenix Alternatives Aeterna Zentaris Alternatives Lipella Pharmaceuticals Alternatives MetaVia Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADXS Stock Free ADXS Stock Alerts